SILO

Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting post-traumatic stress disorder (PTSD).

SARASOTA, FLA., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), ”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that company representatives will participate in the upcoming IPAC-RS 2026 Nasal Innovation Forum to be held September 16-17, 2026, in Jersey City, New Jersey.

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate

Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents Access to AMD Developer Cloud credits, AI development tools and technical resources to support next-generation enterprise AI agents

$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon the exercise in full of warrants in cash

NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing

Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system

Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA., June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.